Blood -- Central role of Sp1-regulated CD39 in hypoxia/ischemia protection

Blood, Vol. 113, Issue 1, 224-232, January 1, 2009

Central role of Sp1-regulated CD39 in hypoxia/ischemia protection
Blood Eltzschig et al. 113: 224

Supplemental materials for: Eltzschig et al

Files in this Data Supplement:

Figure S1. Dimethyloxaloylglycine (DMOG) treatment results in cardiac CD39 induction (JPG, 54.4 KB) -
(A) To study the effects of DMOG on cardiac CD39 expression, C57BL/6 mice were treated with1mg i.p. DMOG. Hearts were excised after indicated time periods, and CD39 transcript levels were determined by real-time RT-PCR. Beta-actin was used as internal standard to control for starting template. (B) Immunohistochemistry for CD39 following DMOG treatment.
Figure S2. Cardiac ATP, AMP, and adenosine levels following ischemia (JPG, 38.4 KB) -
Cardiac tissues derived from cd39^−∕− or corresponding littermate controls (cd39^+/+) following sham operation (C, control) or myocardial ischemia (60 min of coronary artery ligation) were flash frozen and nucleotide levels (ATP, AMP or adenosine) were determined via HPLC.